The developments in the warts therapeutics market have been characterized as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as launches, expansion, enhancement as well as relocation. Inorganic growth strategies witnessed in the market were mergers & acquisitions, partnership, collaborations, alliance, and agreement & joint ventures. These activities have paved way for expansion of business and customer base of market players.
Teva Pharmaceutical Industries Ltd, and Bausch Health Companies, Inc – Notable Market Players in Warts Therapeutics Market
Market leaders operating in the market have undertaken various organic growth strategies in the warts therapeutics market. The Warts Therapeutics market majorly consists of the players Bausch Health Companies Inc., Nielsen BioSciences, Inc., Euro Vital Pharma GmbH, Cipla Inc., Koninklijke Utermöhlen NV, Novan, Inc., Scholl’s Wellness Company, TEVA PHARMACEUTICAL INDUSTRIES LTD, Verrica Pharmaceuticals Inc., GlaxoSmithKline plc., and AIM ImmunoTech Inc. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the warts therapeutics market:
| Year | News |
| Apr-2021 | Teva Pharmaceuticals has launched First Generic Version of Absorica (isotretinoin) Capsules for Severe Recalcitrant Nodular Acne warts. Oral isotretinoin is a promising therapeutic choice for patients with refractory facial plane warts. |
| Mar-21 | Verrica Pharmaceuticals Inc. and Torii Pharmaceutical Co., Ltd. has entered into collaboration and license agreement to develop and commercialize product candidates that contain a topical formulation of cantharidin for the treatment of molluscum contagiosum and common warts in Japan, including VP-102. |
| Mar-2019 | Nielsen BioSciences has presented phase II clinical trial results at the American Academy of Dermatology for Successful Treatment of Common Warts with Candida Extract. |
| Oct-2019 | Novan has expanded its proprietary product pipeline for external genital warts by submitting request for a pre-IND application with the U.S. Food and Drug Administration (FDA) for new product candidate, SB207. |
